Table 1.
Individual Demographic Characteristics with Baseline and Week 24 Clinical Measurements
| Baseline Characteristics | Change in Clinical Characteristics | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subject | Age (y) | Sex | CD4 (cells/ mL) | ARVs | BMI (kg/m2) | Heart Fat (%) | Liver Fat (%) | BP (mmHg) | Aldosterone (ng/dL) | ALT (U/L) | AST (U/L) | |||||||
| BSL | Wk 24 | BSL | Wk 24 | BSL | Wk 24 | BSL | Wk 24 | BSL | Wk 24 | BSL | Wk 24 | BSL | Wk 24 | |||||
| 1 | 61 | M | 860 | ABC/3TC/ DTG | 30.6 | 30.3 | 0.6 | 0 | 8 | 20 | 133/69 | 122/79 | 10.1 | 20.4 | 26 | 25 | 27 | 24 |
| 2 | 37 | F | 1305 | ABC/3TC/ DTG | 34.8 | 34.4 | 8.1 | 0.9 | 35 | 45 | 128/80 | 113/71 | 10.1 | 10.4 | 64 | 21 | 55 | 16 |
| 3 | 62 | M | 422 | ABC/3TC/ DTG | 27.8 | 27.7 | 0.7 | 4.5 | 9 | 10 | 123/74 | 132/85 | 10.4 | 13.7 | 39 | 26 | 33 | 27 |
| 4 | 50 | F | 1341 | ABC/FTC/ TDF | 42.8 | 43.4 | 1.5 | 4.2 | 5 | 24 | 149/76 | 110/74 | 9.9 | 106 | 41 | 27 | 39 | 31 |
| 5 | 60 | M | 759 | ABC/3TC/ DTG | 32.3 | 33.4 | 1.5 | 1.1 | 10 | 32 | 144/86 | 144/89 | 6.4 | 7.5 | 45 | 45 | 43 | 41 |
| Total, Median | 60 | - | 860 | - | 32.3 | 33.4 | 1.5 | 1.1 | 8.6 | 24 | 133/76 | 122/79 | 10.1 | 13.7 | 41 | 26 | 39 | 27 |
BSL = Baseline, ABC= abacavir, 3TC = lamivudine, DTG = dolutegravir, FTC = emtricitabine, TDF=tenofovir